US FDA approves BioMarin's Brineura for children under 3 years with CLN2 disease
BioMarin Pharmaceutical Inc. announced that the US Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for Brineura (cerliponase alfa) to slow the loss of ambulation in children of all ages …